Register today to attend Real-World Data Digital Week. This free-to-attend clinical webinar series explores topics surrounding Real-World Data, Artificial Intelligence and discusses the role of RWE in regulatory environments. Gain insights from industry leaders and unlock new ideas and opportunities to help you utilise the benefits of RWE. Interested in future sponsorship opportunities? Please contact

DAY 1 – March 7, 2023

Break through the Noise: Real Ways Real-World Data and AI are Transforming Research and Decision Making
9am EST / 2pm GMT / 3pm CET

Chronic diseases represent the fastest growing area of disease burden and cost. For conditions in immunology, neuroscience and cardiometabolism, real-world data (RWD) and artificial intelligence (AI) technologies are integral to generating real-world evidence and paving the road to more precise treatments and care. While there is a lot of noise around these capabilities, there is less clarity on how these tools should be applied. However, there is clarity on how to best leverage these data and tools in the most impactful ways. Join Dr. Richard Gliklich, CEO of OM1, as he explores:

  • Accelerating research and analytics with condition-focused real-world datasets
  • Increasing scale and decreasing cost of prospective research with evidence generation networks and automated registries
  • Generating diagnoses, treatment, risk, and trial insights with RWD and AI phenotyping technology


Richard Gliklich, MD
Chief Executive Officer

View More Details +

A Complete Picture of US Health: How AI Can Unlock Billions of Data Points
10am EST / 3pm GMT / 4pm CET

The height of the pandemic in 2020 and 2021 highlighted one of the biggest challenges we face as a Life Sciences community today. That of acquiring data reflecting today’s care and treatment effects in the real world and gathering meaningful knowledge from it.

The promise of healthcare data at an unprecedented scale is real, but the sheer volume and complexity of real-world data (RWD) from disparate data sources and disease-state silos can make realizing this promise very difficult. With AI, we have the potential to normalize and analyze messy and unstructured data across billions of real-world encounters. The question is how do we thoughtfully do that, recognizing the specific clinical context in various situations, and how do we apply it to generate critical insights?

In this session, we will cover:

  • Deploying expert-led AI on nearly 80 million patient lives to address biopharma’s most pressing research challenges
  • Using AI to generate research and treatment insights across disease and data silos in days, not weeks
  • Generating new research hypotheses and questions to advance use cases like clinical trial design, label expansion, safety monitoring, and more


Ryan Ahern, MD
Chief Medical Officer

Harshita Ravishankar
Director Research Solutions

View More Details +

The Innovative Uses of RWE and Insights to the Future
11am EST / 4pm GMT / 5pm CET

  • RWE Generation in Rare Diseases/Conditions
  • Challenges and Opportunities in the Rare Disease Space
  • Understanding the difficulty in accessing RWD to generate evidence


Luis Prieto
Global Real World Evidence Director

Alexander Cole
Executive Director, Global Head Epidemiology and Real-World Science
Alexion-AstraZeneca Rare Disease

View More Details +

DAY 2 – March 8, 2023

The Evolving Role of Real-World Evidence in Drug Development
9am EST / 2pm GMT / 3pm CET

In recent years there has been a shift in how real-world evidence (RWE) is viewed by the pharmaceutical industry. Due to the examples set throughout the COVID-19 pandemic, manufacturers are increasingly considering RWE as an end-to-end solution that can be utilised throughout the drug development process from initial research & development all the way to post-marketing activities. This increasing focus on RWE has led to the launch of several frameworks which formalise the standards for high-quality RWE. With this in mind, this session will explore the current and evolving use-cases for RWE in the drug development process, with a particular focus on health-technology assessment. Topics covered in this session will include:

  • Current and evolving use-cases for RWE in the drug discovery process (across clinical development, market access, and post-marketing activities)
  • RWE frameworks and the formalisation of RWE standards
  • Challenges and opportunities for the future use of RWE


Declan Summers
UK Real-World Evidence Lead
Costello Medical

Sheela Upadhyaya
Life Sciences Consultant Specialising in Rare Diseases

View More Details +

Real-World Evidence for Regulatory Uses
10am EST / 3pm GMT / 4pm CET

Real-world evidence (RWE) is increasingly being used for global regulatory uses based on disease burdens, medication uses, adherence/persistence patterns, patient-reported outcomes (PROs), and treatment patterns/journeys. This presentation will cover some regulatory trends where real-world data (RWD) can be valuable and increasingly harnessed.

Learning Objectives

  • Use RWE to support regulatory decisions in key jurisdictions
  • Examine the roles of RWD and RWE for medicines regulation
  • Share several best practices and trends when harnessing RWD


Kelly H. Zou, PhD, PStat®, FASA
Head of Global Medical Analytics and Real-World Evidence
Viatris Inc.  

View More Details +

REGISTER NOW – Please select the webcast(s) you wish to attend and enter your contact details

DAY 1 – March 7, 2023

DAY 2 – March 8, 202